Related Experiment Video
Updated: Jul 15, 2025
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
Published on: July 6, 2012
Development of dual-mode ELISA based on ALP-catalyzed APP hydrolysis for IL-6 detection
Shijie Cao1, Leyao Li2, Hongwei An3
1CAS Key Laboratory of Quantitative Engineering Biology, Guangdong Provincial Key Laboratory of Synthetic Genomics and Shenzhen Key Laboratory of Synthetic Genomics, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China; Guangxi University of Chinese Medicine, Nanning 530001, China.
A novel enzyme-linked immunosorbent assay (ELISA) detects low levels of interleukin 6 (IL-6) for early cerebral infarction diagnosis. This method offers significantly improved sensitivity for diagnosing this critical condition.
Area of Science:
- Biochemistry
- Immunology
- Medical Diagnostics
Background:
- Accurate detection of interleukin 6 (IL-6) is vital for early cerebral infarction diagnosis.
- Low IL-6 abundance in cerebral infarction poses a diagnostic challenge.
- Current diagnostic methods lack sufficient sensitivity for low-abundance IL-6.
Purpose of the Study:
- To develop a highly sensitive enzyme-linked immunosorbent assay (ELISA) for detecting low concentrations of IL-6.
- To utilize the fluorescence properties of 4-aminophenol phosphate (APP) for enhanced IL-6 detection.
- To establish a dual-mode ELISA for improved in vitro diagnostics of cerebral infarction.
Main Methods:
- Developed an ELISA integrating alkaline phosphatase (ALP)-catalyzed APP hydrolysis with optical signal detection.
- Employed 4-aminophenol, the product of APP hydrolysis, for colorimetric IL-6 quantification.
- Utilized changes in APP fluorescence for sensitive IL-6 detection, correlating with concentration.
- Validated the assay's performance in distinguishing between cerebral infarction patients and healthy volunteers.
Main Results:
- Achieved a colorimetric detection limit of 0.1 ng/mL for IL-6.
- Established a fluorescence-based detection limit of 0.001 ng/mL for IL-6, 100 times more sensitive than conventional methods.
- Demonstrated a linear relationship between APP fluorescence and IL-6 concentration over a wide range.
- Successfully differentiated samples from cerebral infarction patients and controls.
- Correlated IL-6 levels with the severity of cerebral infarction symptoms.
Conclusions:
- The developed dual-mode ELISA offers high sensitivity for detecting low-abundance biomarkers like IL-6.
- This assay shows significant potential for accurate early diagnosis and severity assessment of cerebral infarction.
- The method provides a promising tool for in vitro diagnostics, improving patient outcomes.
